Lexicon Pharmaceuticals I... (LXRX)
| Bid | 0.57 |
| Market Cap | 206.05M |
| Revenue (ttm) | 31.08M |
| Net Income (ttm) | -200.4M |
| EPS (ttm) | -0.63 |
| PE Ratio (ttm) | -0.9 |
| Forward PE | -1.82 |
| Analyst | Hold |
| Ask | 0.6 |
| Volume | 9,481,580 |
| Avg. Volume (20D) | 15,325,924 |
| Open | 0.50 |
| Previous Close | 0.51 |
| Day's Range | 0.50 - 0.59 |
| 52-Week Range | 0.28 - 2.45 |
| Beta | 1.03 |
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The compan...
Analyst Forecast
According to 4 analyst ratings, the average rating for LXRX stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 601.75% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call TranscriptLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q4 2024 Earnings Conference Call March 6, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate S...
